 |
 |
|
|
|  PubMed
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 May 1994 | Volume 120 Issue 9 | Pages 784-791
Objective: To review the structure, mechanism of action, pharmacologic features, and clinical trial results of the newer purine analog, 2-chlorodeoxyadenosine (2-CdA).
Data Sources and Study Selection: English-language medical literature review of more than 70 articles.
Data Synthesis: 2-Chlorodeoxyadenosine is unique compared with traditional antimetabolite drugs in that it is equally active against dividing and resting lymphocytes, which may be especially important in indolent lymphoid malignancies, such as chronic lymphocytic leukemia, because most cells in these disorders are in the resting phase. In patients with alkylator-refractory chronic lymphocytic leukemia who were treated with 2-CdA, 44% achieved a response (4% complete responses, 40% partial responses), and 54%, scored as nonresponders, had a sustained reduction in their peripheral lymphocytosis. Patients with untreated chronic lymphocytic leukemia had an 85% response rate (25% complete responses, 60% partial responses). Patients with previously treated low-grade lymphoma achieved an overall response rate of 43%. The most striking clinical effects of this drug have been seen in hairy cell leukemia, in which a single course of therapy induces complete remissions in 85% of partial remissions in 12%. Activity has also been shown in cutaneous T-cell lymphoma and the myeloid leukemias.
Conclusions: 2-Chlorodeoxyadenosine is a newer purine analog with potent activity in the treatment of indolent lymphoproliferative diseases and illustrates the model for rational drug development.
Author and Article Information
From the Ida M. and Cecil H. Green Cancer Center, Scripps Clinic and Research Foundation, La Jolla, California.
DIAGNOSIS AND TREATMENT
2-Chlorodeoxyadenosine: A Newer Purine Analog Active in the Treatment of Indolent Lymphoid Malignancies
Requests for Reprints: Alan Saven, MD, Scripps Clinic and Research Foundation, 10666 North Torrey Pines Road, La Jolla, CA 92037.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  K. M. King, V. L. Damaraju, M. F. Vickers, S. Y. Yao, T. Lang, T. E. Tackaberry, D. A. Mowles, A. M. L. Ng, J. D. Young, and C. E. Cass A Comparison of the Transportability, and Its Role in Cytotoxicity, of Clofarabine, Cladribine, and Fludarabine by Recombinant Human Nucleoside Transporters Produced in Three Model Expression Systems Mol. Pharmacol., January 1, 2006; 69(1): 346 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Nieva, K. Bethel, and A. Saven Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia Blood, August 1, 2003; 102(3): 810 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Azuma, P. Huang, A. Matsuda, and W. Plunkett 2'-C-Cyano-2'-deoxy-1-{beta}-D-arabino-pentofuranosylcytosine: A Novel Anticancer Nucleoside Analog that Causes Both DNA Strand Breaks and G2 Arrest Mol. Pharmacol., April 1, 2001; 59(4): 725 - 731. [Abstract] [Full Text]
|
|
|
|
|
|
A. Saven and C. Burian Cladribine Activity in Adult Langerhans-Cell Histiocytosis Blood, June 15, 1999; 93(12): 4125 - 4130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Iwasaki, P. Huang, M. J. Keating, and W. Plunkett Differential Incorporation of Ara-C, Gemcitabine, and Fludarabine Into Replicating and Repairing DNA in Proliferating Human Leukemia Cells Blood, July 1, 1997; 90(1): 270 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hortelano and L. Bosca 6-Mercaptopurine Decreases the Bcl-2/Bax Ratio and Induces Apoptosis in Activated Splenic B Lymphocytes Mol. Pharmacol., March 1, 1997; 51(3): 414 - 421. [Abstract] [Full Text] [PDF]
|
|
